• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical hypertension. >Maintaining Goal Blood Pressures After Switching From Olmesartan to Other Angiotensin Receptor Blockers
【24h】

Maintaining Goal Blood Pressures After Switching From Olmesartan to Other Angiotensin Receptor Blockers

机译：从奥美沙坦改用其他血管紧张素受体阻滞剂后维持目标血压

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study assessed blood pressure (BP) goal maintenance in patients controlled with olmesartan monotherapy after switching to another angiotensin type II receptor blocker (ARB). Hypertensive patients prescribed olmesartan monotherapy were identified from GE Healthcare's Centricity electronic medical record between 2007 and 2011. After documentation of BP goal (<140/90 mm Hg) attainment, patients were placed into the continuation cohort if olmesartan monotherapy was maintained or into the switch cohort if they were changed to irbesartan, losartan, or valsartan. Follow-up assessments were the first BP measurement 28 to 390 days after attaining BP goal (continuation cohort) or after prescribing an alternative ARB (switch cohort). Of 3412 patients included (3027 continuation cohort, 385 switch cohort), 52% were women and mean age was 58.0 years. In the switch cohort, 310 (80.5%) were switched to losartan (n=236), irbesartan (n=58), or valsartan (n=16) monotherapy and 75 (19.5%) were switched to combination antihypertensive therapy. Mean baseline and follow-up BP were 122.5/75.8 mm Hg and 126.6/77.6 mm Hg, respectively, in the continuation cohort (P<.001) and 123.5/75.4 mm Hg and 129.6/78.5 mm Hg, respectively, in the switch cohort (P<.001). BP goal maintenance was 78.7% and 72.2% in the continuation and switch cohort, respectively (odds ratio, 0.707; 95% confidence interval, 0.555-0.899). Patients who continued on olmesartan monotherapy after attaining BP goal had a higher percentage of BP goal maintenance than patients who switched therapy.
机译：这项研究评估了接受奥美沙坦单药治疗的患者在切换至另一种II型血管紧张素受体阻滞剂（ARB）后的血压维持目标。从2007年至2011年之间，从GE Healthcare的Centricity电子病历中识别出了接受奥美沙坦单药治疗的高血压患者。在达到BP目标（<140/90 mm Hg）的记录后，如果维持奥美沙坦单药治疗或改用其他药物，则将患者纳入继续队列如果将他们改为irbesartan，losartan或valsartan。随访评估是在达到BP目标后28到390天（连续队列）或开出替代性ARB（转换队列）后的第一次BP测量。在3412例患者中（3027例连续队列，385例转换队列），女性占52％，平均年龄为58.0岁。在转换队列中，将310（80.5％）转换为氯沙坦（n = 236），厄贝沙坦（n = 58）或缬沙坦（n = 16）单药治疗，将75（19.5％）转换为联合降压药。连续队列的平均基线和随访血压分别为122.5 / 75.8 mm Hg和126.6 / 77.6 mm Hg（P <.001），开关组分别为123.5 / 75.4 mm Hg和129.6 / 78.5 mm Hg队列（P <.001）。在连续队列和切换队列中，BP的目标维持率分别为78.7％和72.2％（赔率，0.707; 95％置信区间，0.555-0.899）。在达到BP目标后继续接受奥美沙坦单药治疗的患者，其BP目标维持率要高于转换治疗的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号